Literature DB >> 19787328

[Hearing loss and gait ataxia without dizziness. Hemosiderosis].

L Albrecht1, S Gabriel, A Packebusch, M Roth, K H Beine, F Faltraco.   

Abstract

Superficial cerebral hemosiderosis is characterized by sensorineural hearing loss, gait ataxia and pyramidal signs with irreversible myelopathy. It is caused by chronic hemorrhage into the subarachnoid space with hemosiderin deposition in the subpial, leptomeningeal and subependymal layers. Imaging of the entire neuroaxis is indicated to localize a source of bleeding, including cerebral and spinal angiography when necessary. Taking into account clinical signs and symptoms the interpretation of T2*-weighted images allows the radiologist to set the course for the optimal therapeutic regimen.

Entities:  

Mesh:

Year:  2009        PMID: 19787328     DOI: 10.1007/s00117-009-1925-9

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  5 in total

1.  [Hemosiderosis of the central nervous system due to recurrent subarachnoid hemorrhage in myxopapillary ependymoma of the cauda equina].

Authors:  A Hillemanns; A Kastrup; H Kraph
Journal:  Rofo       Date:  2001-09

2.  [Superficial cerebral hemosiderosis].

Authors:  Josef G Heckmann; Cornelia Möbius; Christoph Lang; Gregor Richter; Stefan Schwab
Journal:  Med Klin (Munich)       Date:  2008-11-15

Review 3.  [Superficial siderosis of the CNS. 2 cases and a review of the literature].

Authors:  A Hug; M Hartmann; A Grau
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

4.  Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches.

Authors:  V I Leussink; P Flachenecker; D Brechtelsbauer; M Bendszus; U Sliwka; R Gold; G Becker
Journal:  Acta Neurol Scand       Date:  2003-01       Impact factor: 3.209

Review 5.  Superficial siderosis of the central nervous system.

Authors:  J M Fearnley; J M Stevens; P Rudge
Journal:  Brain       Date:  1995-08       Impact factor: 13.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.